CD49b, a Major Marker of Regulatory T-Cells Type 1, Predicts the Response to Antiviral Therapy of Recurrent Hepatitis C after Liver Transplantation

Table 2

Demographic data of the cohort.

Characteristics	Distribution
Cohort study	27 patients
Inclusion date	August 2002 to January 2004
Time after transplant (year)*	3 (1, 8)
Age at selection*	56 (27, 68)
Gender
Male	20
Female	7
HCV genotype**	Gen 1: 𝑛=18 (67%), Gen 2: 𝑛=1 (4%); Gen 3: 𝑛=5 (18%), Gen 4: 𝑛=3 (11%)
Immunosuppression	Tacrolimus: 𝑛=16 (59%); Cyclosporine: 𝑛=11 (41%)
Metavir 𝐹 score at inclusion	𝐹1:𝑛=15; 𝐹2: 𝑛=8; 𝐹3: 𝑛=3; 𝐹4: 𝑛=1
Prothrombin time (%)
Mean	90 ± 9
Median (min; max)	90 (59; 107)
AST/ALT (UI/L)
(mean)	75 ± 45/100 ± 60
(median, min; max)	58 (24; 196)/82 (32; 293)
Bilirubin blood level at inclusion (µmol/L)	15.7 ± 10.2
Viral load (log)	6.59 ± 0.24

∗Median value (min, max)
** 𝑛 = number of patients.